October 1, 2007 / 11:37 AM / in 10 years

Amylin says Symlin use without mealtime insulin not approvable

Oct 1 (Reuters) - Amylin Pharmaceuticals Inc AMLN.O said U.S. health regulators issued a “not approvable” letter for Symlin use without mealtime insulin in patients with type 2 diabetes who have not achieved desired glucose control.

The Food and Drug Administration has approved SymlinPen 120 and SymlinPen 60 pen-injector devices to administer Symlin injection to improve mealtime glucose control, the San Diego-based biotechnology company said in a statement.

Symlin is currently approved in the United States for patients with type 2 or type 1 diabetes who use mealtime insulin and need improved glucose control. (Reporting by Bhaswati Mukhopadhyay in Bangalore)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below